TABLE 1.
Study population and baseline characteristics.
| Telitacicept 160 mg (N = 14) | Telitacicept 240 mg (N = 15) | All patients (N = 29) | |
|---|---|---|---|
| Age, years, mean ± SD | 42.6 ± 13.78 | 45.5 ± 10.60 | 44.1 ± 12.10 |
| Sex, n (%) | |||
| Male | 6 (42.9) | 7 (46.7) | 13 (44.8) |
| Female | 8 (57.1) | 8 (53.3) | 16 (55.2) |
| Duration of MG, month (m) | 50.11 (50.33) | 73.56 (90.1) | 62.24 (73.31) |
| QMG score a , mean ± SD | 18.4 ± 6.01 | 19.3 ± 4.43 | 18.9 ± 5.17 |
| MG clinical absolute score b , mean ± SD | 23.1 ± 8.47 | 24.8 ± 9.46 | 24.0 ± 8.88 |
| MGFA clinical classification | |||
| Class II, n (%) | 7 (50.0) | 9 (60.0) | 16 (55.2) |
| Class III, n (%) | 7 (50.0) | 6 (40.0) | 13 (44.8) |
| AChR‐Abs | |||
| Negative, n (%) | 0 (0) | 0 (0) | 0 (0) |
| Positive, n (%) | 14 (100.0) | 15 (100.0) | 29 (100.0) |
| Any concomitant MG medications, n (%) | 14 (100.0) | 15 (100.0) | – |
| Cholinesterase inhibitor | |||
| Pyridostigmine bromide, n (%) | 14 (100.0) | 15 (100.0) | 29 (100.0) |
| Steroid | 8 (57.1) | 8 (53.3) | 16 (55.2) |
| Prednisone acetate, n (%) | 7 (50.0) | 6 (40.0) | 13 (44.8) |
| Methylprednisolone, n (%) | 1 (7.1) | 1 (6.7) | 2 (6.9) |
| Prednisone, n (%) | 0 (0) | 1 (6.7) | 1 (3.4) |
| Immunosuppressant, n (%) | 4 (28.6) | 8 (53.3) | 12 (41.4) |
| Tacrolimus, n (%) | 3 (21.4) | 7 (46.7) | 10 (34.5) |
| Azathioprine, n (%) | 1 (7.1) | 0 (0) | 1 (3.4) |
| Mycophenolate mofetil, n (%) | 0 (0) | 1 (6.7) | 1 (3.4) |
Abbreviations: AChR‐Abs, acetylcholine receptor antibodies; MG, myasthenia gravis; MGFA, Myasthenia Gravis Foundation of America; QMG, quantitative myasthenia gravis.
a
Total QMG scores range from 0 (none) to 39 (severe).
b
Total MG absolute clinical scores range from 0 (normal) to 60 (severe).